Woodford Investment Management (WIM) is seeking to raise an initial £200m for the launch of the Woodford Patient Capital investment trust, a portfolio of 50-100 quoted and unquoted businesses.
Contrary to speculation that manager Neil Woodford’s second offering at WIM would focus wholly on biotechnology companies, the trust will invest broadly in firms with “outstanding” intellectual property, including those higher up the cap scale. Early-stage investments, which are eventually expected to constitute 75% of the portfolio, will centre on areas such as “disruptive” alternative finance as well as medical science firms. Aimed at investors with a five-year time horizon, the trust will charge no management fee, instead levying a performance fee that will be payable in ordinary s...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes